Diatech Pharmacogenetics Acquires SensoQuest and Launches Labcycler Thermal Cycler Entering Lab Instrumentation Market
German engineering meets Italian manufacturing in a compact, highly reliable thermal cycler for research and diagnostic laboratories JESI, Italy, 22nd October 2026 – Diatech Pharmacogenetics, an Italian molecular diagnostics company serving the precision medicine market internationally, is expanding into laboratory instrumentation with Labcycler, a compact PCR thermal cycler built on three principles: robustness, accuracy and […]
Diatech Pharmacogenetics joins the Human AI Foundation as a founding member
Connecting business and research to advance people-centred artificial intelligence. Oliva Alberti, CEO of Diatech Pharmacogenetics, serves as President. Diatech Pharmacogenetics is a founding member of the Human AI Foundation, presented on 19 October 2026 at the University of Macerata, Italy. The initiative aims to help Italian businesses and organisations adopt artificial intelligence in ways that […]
Diatech Pharmacogenetics tra i soci fondatori della Fondazione Human AI
German engineering meets Italian manufacturing in a compact, highly reliable thermal cycler for research and diagnostic laboratories JESI, Italy, 22nd October 2026 – Diatech Pharmacogenetics, an Italian molecular diagnostics company serving the precision medicine market internationally, is expanding into laboratory instrumentation with Labcycler, a compact PCR thermal cycler built on three principles: robustness, accuracy and […]
Diatech Pharmacogenetics Expands Collaboration with Merck to Enhance Patient Access to Personalized Medicine in the Middle East and Africa
Diatech Pharmacogenetics (Jesi, Italy) announced an expansion of its collaboration with Merck Serono Middle East Ltd., affiliates of Merck KGaA (“Merck”). The collaboration aims to improve patient access to RAS biomarker testing in the Middle East and Africa (MEA) regions. Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all […]
Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing
SAN DIEGO, Calif., Oct. 27, 2015 — Agena Bioscience announced today the planned commercial launch of its CE-IVD marked MassARRAY® Dx PLUS assays for gene-specific mutation testing to aid in the selection of targeted therapy regimens. Agena Bioscience will introduce the first diagnostic kits in partnership with Diatech Pharmacogenetics. The MassARRAY Dx PLUS assays improve […]